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Abstract
Background: Obesity is associated with morbidity, mortality, and increased health care costs.
Few studies have examined the impact of obesity on outpatient office visits. The purpose of this
study was to determine if outpatient visits by obese persons required more time with the provider
and more prescription medication management compared to visits made by non-obese persons.
Methods: Obesity status was determined for 9,280 patient visits made by persons aged 18 years
or older in the 2006 National Ambulatory Medical Care Survey. Multivariate analyses compared
obese and non-obese visits, stratified by sex, for duration of the visit and the number of medications
mentioned at the visit.
Results: Average duration of visit was higher among visits with patients determined to be obese.
However, these differences were not considered significant after statistical testing. Visits made by
obese female patients were significantly more likely to involve more than two prescription
medications (OR 1.26, 95% CI 1.05 - 1.51) and visits made by obese male patients were significantly
more likely to involve more than two prescription medications (OR 1.46, 95% CI 1.16 - 1.83) as
compared to visits made by non-obese patients.
Conclusion: Time spent with the provider was found to be greater among visits with obese
patients, but not significantly different from visits with non-obese patients. The number of
medications for each visit was found to be significantly greater for visits where the patient was
considered to be obese. Increased time for the visit and increased numbers of medication for each
visit translate into increased costs. These findings document the impact of obesity on our health
care system and have great implications on medical care cost and planning.
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Background
Obesity continues to be an important health problem in
the United States. Over the past two decades, the trends in
the prevalence of overweight and obesity have steadily
risen and began to level off in 2002 with 65.7% of adults
classified as overweight or obese and 30.2% obese [1].
More recent estimates report that 66.3% of adults are
overweight or obese, and 32.2% are obese [2].
With the sustained high rates of overweight and obesity, a
heavy cost is levied on the U.S. health care system. Accord-
ing to Finkelstein and colleagues, the direct medical cost
of overweight and obesity in the U.S. was $78.5 billion in
1998 [3] and more recent work by Finkelstein and col-
leagues estimates that medical costs attributable to obesity
could run as high as $147 billion in 2008 [4]. Others
report that obesity accounts for about 6-10% of medical
expenditures in the United States [5-8]. Thorpe and col-
leagues estimated that between 1987 and 2001, the
increase in obesity prevalence accounted for a 12 percent
increase in overall health care spending with much of the
increase coming from the treatment of co-morbidities of
obesity such as hyperlipidemia, heart disease and diabetes
[9]. Pearson further noted that as overweight and obesity
rates continued to increase from 1995 through 2004,
there was an even greater increase in the numbers of visits
to office-based physicians for the treatment of diabetes
[10]. After controlling for chronic diseases, Raebel esti-
mated that for each unit of BMI increase, costs related to
inpatient and outpatient health care increased by 2.3%
[11]. These studies indicate that as obesity increases in the
U.S. population, more treatment and expense will be ren-
dered for not only obesity itself, but also for its costly co-
morbidities.
Many studies have discussed the overall cost impact of
obesity, while few have examined specific drivers of cost
at the patient-visit level. It is thought that by measuring
services at the patient-visit level, costs related to obesity
can be quantified. Two measurable costs associated with
ambulatory health care include provider time and pre-
scription drug dispensing and management. These two
measures were chosen because of their immediate impact
on the office visit. Therefore, the purpose of this study was
to determine if visits made to office-based physicians by
obese persons required more time with the provider and




The data for these analyses were taken from the 2006
National Ambulatory Care Medical Survey (NAMCS). The
NAMCS is a representative survey of non-federally
employed office-based physician visits, including com-
munity health centers, conducted yearly by the Centers for
Disease Control and Prevention's (CDC) National Center
for Health Statistics (NCHS) and is considered to be
exempt from review by the CDC's Institutional Review
Board. This survey uses a multistage probability design
employing the use of geographic primary sampling units
(PSUs), physician practices within the PSUs and patient
visits within the physician practices. The unit of analysis
for this survey is the office visit. Information about the
visit including patient demographics, diagnoses, reason
for visit, procedures and medications prescribed and
monitored during the visit, among other information, are
collected by the office staff using patient record forms over
a one-week period [12].
The variables that were used in this study included the fol-
lowing: age, race, and sex of the patient, the body mass
index (BMI) in kg/m2 (which was calculated by weight
and height measurements for the patient at the time of
visit), a diagnosis of obesity on the patient's record, pay-
ment source, major reason for the visit, total number of
chronic conditions at the time of the visit, the number of
medications listed for the visit, and the amount of time
spent with the provider during the visit.
Age was categorized into four groups including those aged
18-34 years, 35-49 years, 50-64 years, and aged 65 years or
older. Race was classified as white, black, and other. Sex
was classified as either male or female. Payment source
was classified as private pay, Medicare, Medicaid, or other
sources such as workers compensation or charity care
combined with unknown sources. There were five possi-
ble classifications of reason for the visit. They were: a new
problem, a routine visit for a chronic problem, a visit
made for a flare-up of a chronic problem, a visit made for
pre- or post-surgery review, or a visit made for preventive
care. The survey questionnaire also determined up to 14
co-morbid chronic conditions for the patient during the
visits. They are: arthritis, asthma, cancer, cerebrovascular
disease, congestive heart failure, chronic renal failure,
chronic obstructive pulmonary disease, depression, diabe-
tes, hyperlipidemia, hypertension, ischemic heart disease,
obesity, and osteoporosis.
Statistical Analyses
All analyses were conducted using SUDANN® to take into
account the complex sampling design of the survey [13].
Office visits were stratified into those made by persons
with 18.5 kg/m2 ≤ BMI <30 kg/m2 and those made by per-
sons with BMI ≥30 kg/m2 or who in lieu of a BMI value
had a diagnosis of obesity on the patient record. Visits
where the BMI was less than 18.5 kg/m2 or where BMI or
obesity status was not able to be determined were
excluded from analyses. Estimates were made for all co-
variates as well as the average amount of time spent withBMC Public Health 2009, 9:436 http://www.biomedcentral.com/1471-2458/9/436
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the provider during the visit and the average number of
medications prescribed at each visit. All analyses were
stratified by sex of the patient to take into account behav-
ioral differences and care access patterns between males
and females.
Time spent with the provider was rounded to the closest
five minute interval among those with 18.5 kg/m2 ≤ BMI
<30 kg/m2, which is representative of scheduling practices
for office-based physicians. The number of medications
mentioned among those with 18.5 kg/m2 ≤ BMI < 30 kg/
m2 was similarly rounded down to the closest whole
number. The proportion of visits that lasted for more than
20 minutes and the proportion of visits where more than
2 medications were prescribed were estimated for both
BMI strata and by sex. Differences in these proportions
were initially tested using chi-square analyses. These dif-
ferences were further tested using two adjusted logistic
regression models. The first model controlled for age, sex
and race of the patient. The second model further control-
led for payment source, major reason for the visit, and the
total number of co-morbid chronic conditions. All tests
were conducted at an α = 0.05.
Results
A total of 5,806 visits for females and 3,474 visits for
males were analyzed. Few differences among the covari-
ates were noted between the two BMI groups. The propor-
tion of visits across the age groups was similar. Black
females with BMI > 30 kg/m2 had a greater proportion of
visits as compared to Black females with BMI 18.5-29.9
kg/m2. Compared to visits with patients with a BMI ≥ 30
kg/m2, a greater percentage ofpatient visits with a BMI <
30 kg/m2 were with patients without co-morbid, chronic
conditions. Finally, small differences were noted in the
two groups based on the average number of medications
that were mentioned at the visit and the average amount
of time spent with the provider during the visit. Among
female visits, those with a BMI ≥ 30 kg/m2 averaged 23.0
minutes in duration compared to 21.4 minutes for those
where the BMI was 18.5 - 29.9 kg/m2. This represents a 1.6
minute difference. Also among females, visits where the
BMI was ≥ 30 kg/m2, had on average 3.1 medications
mentioned for the visit compared to 2.5 medications
mentioned where the BMI was 18.5 -29.9 kg/m2. Likewise
among male visits, those with BMI ≥ 30 kg/m2 averaged
22.5 minutes in duration compared to 21.2 minutes for
visits where the BMI was 18.5 - 29.9 kg/m2. This repre-
sents a 1.3 minute difference. Finally, among male visits,
the average number of medications was 3.1 for visits
where BMI ≥ 30 kg/m2 compared to 2.6 where the BMI
was 18.5 - 29.9 kg/m2. (Table 1)
Chi-square tests comparing the proportion of visits lasting
longer than 20 minutes showed no significant differences
for either sex. However, for both sexes, significant differ-
ences in the number of medications for each visit were
higher among those where the patient was considered to
be obese. Among female visits where the patient was con-
sidered to be obese, 48.5% had more than two prescribed
medications compared to 38.6% for those visits where the
patient was not considered to be obese (p < .01). Among
male visits where the patient was considered to be obese,
50.3% had more than two prescribed medications com-
pared to 40.8% where the patient was not considered to
be obese (p < .01). (Table 2)
Logistic regression models provided significant differ-
ences for both female and male visits between the two
BMI groups for the likelihood of having more than two
prescription medications while controlling for different
levels of covariates. No significant differences were seen
for amount of time spent with the provider. Among
females visits, the first level of models controlling for age
and race of the patient demonstrated that visits where the
patient was considered to be obese had a 61% greater like-
lihood of having more than two prescribed medications
mentioned at the visit compared to visits where the
patient was not considered to be obese (OR 1.61; 95% CI
1.35 - 1.91). Among male visits, the models controlling
for age and race demonstrated that visits where the patient
was considered to be obese had a 59% greater likelihood
of having more than two prescribed medications men-
tioned at the visit compared to visits where the patient was
not considered to be obese (OR 1.59; 95% CI 1.28 - 1.98).
(Table 3)
The second level of models additionally controlled for
payment source for the visit, number of co-morbid
chronic conditions and major reason for the visit and also
showed significant differences between the two BMI
groups on the number of medications prescribed. No Sig-
nificant differences were seen in these models for amount
of time spent with the provider. Among females, visits
made by patients who were considered to be obese had a
26% greater chance of having more than two prescribed
medications mentioned at the visit as compared to visits
where the patient was not considered to be obese (OR
1.26; 95% CI 1.05-1.51). Among males in the same
model, visits where the patient was considered to be obese
had an 46% increased likelihood of having more than 2
prescribed medications mentioned at the visit as com-
pared to visits where the patient was not considered to be
obese (OR 1.46; 95% CI 1.16-1.83). (Table 3)
Discussion
Results from this study have demonstrated the significant
impact that obesity has on office-based physician visits.
These analyses make a contribution to the literature by
demonstrating the impact of obesity at the level of theBMC Public Health 2009, 9:436 http://www.biomedcentral.com/1471-2458/9/436
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provider, while many other obesity studies speak to soci-
etal costs and overall health system costs of obesity.
The results in this study indicate a greater amount of time
spent with the provider during the visit when the patient
was obese. On average, for visits where females were
obese, the provider spent 1.6 minutes longer with the
patient compared to a visit where the patient was not
obese. For males, providers spent on average 1.3 minutes
longer with obese patients as with non-obese patients.
However, these findings for a difference in time were not
significant. Although, it appears that medical providers
treating obese patients in an outpatient setting prescribed
significantly more medications for obese patients com-
pared to non-obese patients, even after controlling for the
number of co-morbid conditions and the primary reason
for the visit.
Table 1: Characteristics of office-based physician visits made by persons with BMI 18.5 - 29.9 kg/m2 and those with BMI ≥ 30 kg.m2 in 
the United States by sex, 2006
Body Mass Index 18.5-29.9 kg/m2 ≥30 kg/m2
Females Males Females Males
n = 3,114 n = 1,985 n = 2,692 n = 1,489
%, (% S.E.) %, (%S.E.) %, (% S.E.) %, (S.E.)
Age in Years
18-34 20.9, (1.6) 17.5, (1.6) 17.3, (1.3) 10.9, (1.1)
35-49 24.3, (1.2) 23.4, (1.4) 27.6, (1.2) 30.1, (1.7)
50-64 24.9, (1.0) 25.5, (1.4) 32.2, (1.3) 32.7, (1.7)
65+ 29.9, (1.8) 33.6, (2.1) 22.9, (1.6) 26.3, (2.1)
Race
White 86.0, (1.3) 84.2, (1.9) 80.6, (2.1) 87.0, (1.6)
Black 9.7, (1.1) 10.2, (1.3) 16.6, (2.1) 8.5, (1.5)
Other 4.2, (0.7) 5.6, (1.6) 2.8, (0.5) 4.5, (1.1)
Payment Source
Private Pay 56.8, (2.0) 47.8, (2.8) 52.8, (2.0) 53.9, (2.6)
Medicare 24.4, (1.8) 27.9, (2.1) 20.8, (1.4) 23.1, (2.1)
Medicaid 7.7, (0.9) 7.0, (1.3) 12.8, (1.3) 7.2, (1.0)
Other/Unknown* 11.2, (1.0) 17.3, (2.4) 13.6, (1.6) 15.9, (2.3)
Major Reason for Visit
New problem 1.1, (0.3) 1.1, (0.3) 1.7, (0.4) 1.0, (0.3)
Chronic problem, routine 34.5, (1.7) 34.9, (2.2) 32.1, (1.6) 35.5, (2.1)
Chronic problem, flare-up 26.4, (1.8) 35.2, (2.2) 33.5, (2.0) 35.8, (2.5)
Pre/post surgery 8.6, (0.8) 8.4, (0.9) 11.3, (1.0) 9.1, (1.1)
Preventive care 6.7, (0.8) 5.8, (1.2) 5.6, (0.8) 5.1, (0.9)
Unknown 22.8, (2.2) 14.5, (2.2) 15.9, (1.5) 13.5, (2.0)
Number of Co-morbid Chronic Conditions
0 40.2, (2.1) 34.3, (2.1) 26.4, (1.7) 24.0, (2.1)
1-2 41.7, (1.7) 44.7, (2.2) 45.4, (1.6) 48.5, (2.1)
3+ 18.2, (1.3) 21.0, (1.6) 28.3, (2.0) 27.4, (2.2)
Average number of minutes with the provider**
21.4, (0.7) 21.2, (0.7) 23.0, (0.8) 22.5, (0.9)
Average number of medications mentioned at the visit**
2.5, (0.1) 2.6, (0.1) 3.1, (0.1) 3.1, (0.2)
Source: 2006 National Ambulatory Medical Care Survey (NAMCS)
S.E. = Standard Error
* Other sources include workers' compensation and charity care
** Mean, (Standard error of the mean)
Table 2: Comparisons of estimates for visits with BMI 18.5 - 29.9 
kg/m2 and those with BMI ≥ 30 kg/m2 for time spent with the 
provider during visit and number of medications prescribed 
during visit by sex, 2006
Females, n = 5806 18.5 - 29.9 kg/m2 ≥30 kg/m2
%, (% S.E.) %, (% S.E.) p *
% of visits where time spent with provider was > 20 minutes
31.7, (2.5) 32.0, (1.8) .89
% of visits where number of medications was > 2
38.6, (2.2) 48.5, (2.4) <.01
Males, n = 3,474 18.5 - 29.9 kg/m2 ≥30 kg/m2
%, (% S.E.) %, (% S.E.) p *
% of visits where time spent with provider was > 20 minutes
27.8, (2.4) 30.9, (2.4) .16
% of visits where number of medications was > 2
40.8, (2.5) 50.3, (2.7) <.01
Source: 2006 National Ambulatory Medical Care Survey (NAMCS)
* Chi-square test α = 0.05
S.E. = Standard ErrorBMC Public Health 2009, 9:436 http://www.biomedcentral.com/1471-2458/9/436
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Previous research has shown that obesity is related to
increases in health care utilization. Two past studies on
U.S. cohorts have suggested that the greatest impact of
obesity on health care cost and utilization is in outpatient
primary care clinical services. The first study, conducted
by Andreyeva and colleagues using data from the Health
and Retirement Study, found that the average increase in
health care costs associated with a BMI of 30 and higher
(averaging across all obesity classes) for individuals aged
54-69 years old was 33% [14]. In the second study, Ber-
takis and colleagues found that (in a prospective study of
509 adult patients) obesity was associated with an
increased number of primary care visits, diagnostic serv-
ices and primary care clinic charges [15]. The same
researchers, however, did not find an increase in visit
length, but rather that the visit content became more
focused on exercise habits and technical tasks rather than
disease-specific treatments.
Findings similar to the present study have been demon-
strated in other countries using population-based cohorts.
von Lengerke and colleagues demonstrated in their study
that compared to normal weight persons (18.5 - 24.9 kg/
m2), those in Obesity Class I (30.0-34.9 kg/m2) were
more likely to report, over a one-half year period, at least
one visit to a general practitioner and that those in Obes-
ity Class II (35.0 - 39.9 kg/m2) and those in Obesity Class
III (≥ 40 kg/m2) had significantly higher odds of having
high general practitioner use, defined as eight or more vis-
its in a year [16] Other studies found a positive associa-
tion between obesity and use of primary health care
services [17,18]. In these studies, obese patients required
more time with the provider during their visits, and also
required a greater number of prescribed medications. Fur-
thermore, these studies found a direct relationship
between degree of obesity and amount of health care
usage. In simple descriptive analyses, our study showed
that visits where the patient was considered to be obese
had a longer duration compared to visits where the
patient was not considered to be obese. Again though, this
difference was not found to be significant. These findings
do however point to increased resource utilization.
Table 3: Adjusted logistic regressions for the likelihood of spending > 20 minutes with the provider during the visit and the likelihood of 
being prescribed > 2 medications during the visit by sex, 2006
Females, n = 5,806
O.R. 95% C.I.
Amount of time spent with provider during visit > 20 minutes
Model 1: controlling for age and race
BMI ≥ 30 kg/m2 0.99 0.83-1.18
BMI 18.5 - 29.9 kg/m2 reference reference
Model 2: controlling for age, race, payment source, number of chronic conditions and major reason for visit
BMI ≥ 30 kg/m2 1.01 0.85-1.20
BMI 18.5 - 29.9 kg/m2 reference reference
Number of prescribed medications during visit > 2 medications
Model 1: controlling for age and race
BMI ≥ 30 kg/m2 1.61 1.35-1.91
BMI 18.5 - 29.9 kg/m2 reference reference
Model 2: controlling for age, race, payment source, number of chronic conditions and major reason for visit
BMI ≥ 30 kg/m2 1.26 1.05-1.51
BMI 18.5 - 29.9 kg/m2 reference reference
Males, n = 3,474
O.R. 95% C.I.
Amount of time spent with provider during visit > 20 minutes
Model 1: controlling for age and race
BMI ≥ 30 kg/m2 1.14 0.93-1.40
BMI 18.5 - 29.9 kg/m2 reference reference
Model 2: controlling for age, race, payment source, number of chronic conditions and major reason for visit
BMI ≥ 30 kg/m2 1.13 0.92-1.38
BMI 18.5 - 29.9 kg/m2 reference reference
Number of prescribed medications during visit > 2 medications
Model 1: controlling for age and race
BMI ≥ 30 kg/m2 1.59 1.28-1.98
BMI 18.5 - 29.9 kg/m2 reference reference
Model 2: controlling for age, race, payment source, number of chronic conditions and major reason for visit
BMI ≥ 30 kg/m2 1.46 1.16-1.83
BMI 18.5 - 29.9 kg/m2 reference reference
Source: 2006 National Ambulatory Medical Care Survey (NAMCS)BMC Public Health 2009, 9:436 http://www.biomedcentral.com/1471-2458/9/436
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A second finding of this study was that patients with a BMI
≥ 30 kg/m2 received more prescription medication man-
agement during the visit compared to those with BMI < 30
kg/m2. In 2007, it was estimated that prescription drugs
account for approximately 10 percent of total health
expenditures [19] and represent an ever-increasing por-
tion of out-of-pocket expenditures by the individual and
an ever increasing proportion of government spending for
health care [20].
The analyses in this study are in line with prior research
which suggests that prescription medication use is higher
in obese persons compared to non-obese persons. For
example, a study using the Medicare Current Beneficiary
Survey demonstrated that obese Medicare recipients had
higher prescription drug costs and higher health care uti-
lization rates compared to non-obese patients [21]. A sec-
ond example of this phenomenon is the Counterweight
Program in the Framingham Heart Study, where Molenaar
and colleagues found that not only were obese people
using more prescription drugs, but they were more likely
to be prescribed medications for hypertension and hyper-
lipidemia than non-obese patients with the same condi-
tions [22]. Furthermore, a retrospective cohort study
examining hospitalizations, outpatient visits and use of
other health care services showed that obese individuals
were more likely to be hospitalized than non-obese indi-
viduals and that their total medical costs were higher due
largely to costs from prescription medications [9].
Several limitations should be considered when interpret-
ing the results of this study. The most notable limitation
of this study is that exact dollar amount costs were not
determined because the dataset does not collect actual
costs. However, this study does provide insight into rela-
tive resource utilization by persons who are obese, which
shows where the costs are being consumed.
Second, the nature of the NAMCS is that the sampling
unit is a patient visit, not a person. Therefore, it is possible
that one person can be represented in the sample more
than once through multiple visits. However, as noted in
the survey description, most sampling was conducted in
physicians' offices over a limited period of time, specifi-
cally a one-week period. Therefore, the likelihood of hav-
ing one person represented by numerous office visits is
low.
A third limitation of this study is that only data on in-per-
son office visits were collected. A significant percentage of
medication and disease management is conducted over
the telephone, but information on these services was not
collected. If this limitation is true, then it is possible that
the findings of this study may underestimate the impact of
obesity on office-based physician practices.
A fourth limitation of this study was the definition of
obesity and the classification of BMI. Some records within
this dataset did not contain height and weight. However,
they did contain a diagnosis of obesity. Therefore, it was
not possible to further stratify persons with obesity into
the different obese classes. We were able to provide a dis-
tinction between those visits with persons who were obese
and those who were not obese. A better detailed measure-
ment of BMI would be useful in determining a more pre-
cise effect of increasing increments of BMI on healthcare
costs. Even with this limitation, our analyses do provide a
rudimentary look at the impact of obesity on outpatient
visits.
One future direction for study in this area of health serv-
ices should include the impact of obesity on other ancil-
lary services such as dietary, physical therapy, and nursing
services. Obesity is a health problem that pervades all
aspects of health care; not just at the physician-patient
nexus. This study and the body of research in this area
clearly demonstrate that obesity is a problem that is of
great concern for our health care system and will continue
to be a problem in the near future. Improvement in life-
style behavioral interventions and multidisciplinary care
management in the outpatient setting may reduce health
care costs from obesity and its co-morbid conditions.
Conclusion
To our knowledge, this is the first nationally representa-
tive study using the NAMCS to demonstrate the impact of
obesity on provider time and prescriptive practices. The
findings in our study and those of others point to a grow-
ing problem for individual patients and for our overall
health care system due to obesity. Our work used recent
ambulatory care data to provide a more focused look at
the impact of obesity specifically in the outpatient setting.
As our population ages and the demand for the treatment
of chronic disease in the outpatient setting grows, health-
care resources will become more constrained. Therefore, it
is imperative that obesity, which is a modifiable health
issue within the United States, be tackled in order to save
on both individual and societal medical costs.
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